View the Latest: Mortality
Filter
-
-
-
-
COVID-19 leading cause of death ranking
Issue BriefThis updated analysis examines COVID-19's effect on mortality rates, and estimates that in January 2022, COVID-19 was number two on the list of leading causes of death in the U.S.
-
Child and Teen Firearm Mortality in the U.S. and Peer Countries
Issue BriefFirearms were responsible for 20 percent of all child and teen deaths in the U.S. for both 2020 and 2021, compared to an average of less than 2 percent in similarly large and wealthy nations. This puts the U.S. far ahead of peer nations in child and teen firearm deaths.
-
Premature Mortality During COVID-19 in the U.S. and Peer Countries
Issue BriefThis analysis finds that the U.S. had the highest rate of premature deaths amid the COVID-19 pandemic in 2020-2021 among a group of 12 large, wealthy peer countries. The U.S. on average had more than two times the average years of life lost per 100,000 people as the United Kingdom, the country with the next highest rate.
-
Americans’ Experiences With Gun-Related Violence, Injuries, And Deaths
FeatureThis survey examines Americans’ experiences with gun-related incidents such as being threatened with a gun, having a family member killed by a gun, or witnessing someone being shot. The survey also explores worries about gun violence, precautions people report taking to protect their families, how gun owners say they store their guns, and discussions about guns with health care providers.
-
COVID-19 in Metropolitan and Non-Metropolitan Counties
FeatureThese slides compare COVID-19 coronavirus cases and deaths in rural and urban areas.
-
A Snapshot of Cancer Spending and Outcomes
FeatureA Snapshot of Cancer Spending and Outcomes_JAMA 062116 Download VIEW JAMA INFOGRAPHIC…
-
What Are Recent Trends in Cancer Spending and Outcomes?
FeatureThis slideshow compares death rates, years of life lost and disease burden from cancers in the United States to those from other diseases and in other countries. The slideshow also looks at spending on cancers in relation to spending on other diseases and to overall health expenditures.